President Donald Trump signed an executive order on April 18, 2023, directing the Food and Drug Administration (FDA) to expedite reviews of psychedelic drugs like ibogaine for treating mental health conditions such as post-traumatic stress disorder (PTSD). The move aims to accelerate access to new medical research and treatments based on these substances. According to multiple reports, the executive order instructs the FDA to prioritize the review of psychedelics already designated as breakthrough therapy drugs.
Key Takeaways
President Trump signed an executive order to expedite FDA reviews of psychedelic drugs for treating mental health conditions like PTSD. He allocated $50 million for ibogaine research and opened pathways under the Right To Try rule.
- President Trump directed the FDA to prioritize psychedelics designated as breakthrough therapies.
- $50 million will fund federal research into ibogaine, a drug used to treat PTSD in veterans.
- The order allows ibogaine administration to 'desperately ill patients' under the Right To Try rule.
- Ibogaine is currently classified as a Schedule I substance but has shown promise in reducing cravings and withdrawal symptoms.
Trump announced that $50 million will be dedicated to federal research into ibogaine, a drug that veteran groups have said can help treat PTSD. The order also opens a pathway for ibogaine to be administered to 'desperately ill patients' under the FDA's Right To Try rule. Health Secretary Robert F. Kennedy Jr., who has championed the use of drugs like ibogaine, stated that the reforms would pave the way for these substances to be reclassified after successful clinical trials.
During the announcement, podcaster Joe Rogan revealed he had texted Trump about ibogaine as a treatment for depression and PTSD. According to Sky News, Trump responded positively, saying 'Sounds great. Do you want FDA approval? Let's do it.' Veteran Marcus Luttrell also expressed his support, telling Trump that the drug had changed his life for the better.
Ibogaine, derived from a shrub native to Africa, is currently classified as a Schedule I substance by the Drug Enforcement Administration (DEA), grouping it alongside heroin and ecstasy. Despite its legal status, ibogaine has been used in some countries to treat mental health conditions. Studies have shown that ibogaine can cause hallucinations and has been linked to cardiac-related fatalities. However, recent research suggests it may reduce cravings and withdrawal symptoms in patients with substance abuse disorders.
The executive order also includes provisions to improve data sharing between the FDA and the Department of Veterans Affairs, as well as facilitate fast rescheduling of any psychedelic drugs that become FDA approved. This initiative is seen as a significant step toward addressing the mental health needs of veterans and others suffering from severe mental illness.
How this summary was created
This summary synthesizes reporting from 11 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.